For Research Use Only — Not for human or veterinary use.

Education

KPV: Anti-Inflammatory Tripeptide Fragment Research Overview

A research overview of the alpha-MSH-derived tripeptide KPV, its receptor-independent NF-κB mechanism, and the inflammatory bowel disease and immune-signaling research domains it has been studied in.

KPV
All content on this page is for laboratory and academic reference only. This compound is supplied under a Research Use Only framework for in vitro and preclinical investigation by qualified personnel. Nothing on this page is clinical guidance, and it should not be interpreted as instructions for use in humans or animals.

Key Takeaways

  • KPV (Lys-Pro-Val) is a naturally occurring tripeptide corresponding to residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH).[1]
  • Unlike full-length alpha-MSH, KPV does not bind melanocortin receptors or increase intracellular cAMP, and its anti-inflammatory effects are reported to be receptor-independent.[1]
  • In intestinal epithelial and immune cell research models, KPV has been reported to inhibit NF-κB activation by preventing IκBα degradation.[2]
  • KPV is transported into colonic cells via the PepT1 peptide transporter, and oral KPV reduced disease severity in DSS- and TNBS-induced colitis mouse models.[2]
  • A separate murine IBD study reported KPV treatment was associated with earlier recovery, reduced weight loss, and reduced inflammatory infiltrate in colonic tissue.[3]

What It Is

KPV is a naturally occurring tripeptide (lysine-proline-valine) corresponding to the C-terminal fragment, residues 11 through 13, of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid neuropeptide produced in the pituitary gland and various peripheral tissues. KPV research is distinguished from full-length alpha-MSH research by its reported receptor-independent activity — KPV does not bind melanocortin receptors (MC1-5R) or increase intracellular cAMP the way alpha-MSH does, meaning its studied anti-inflammatory effects are mechanistically separate from alpha-MSH's classical hormonal signaling.[1]

Mechanism & Pathway

The mechanism most reported for KPV involves inhibition of NF-κB (nuclear factor kappa B), a transcription factor that governs the expression of many inflammatory genes. In intestinal epithelial and immune cell research models, KPV has been reported to inhibit NF-κB nuclear translocation by preventing degradation of IκBα, the inhibitory protein that normally holds NF-κB inactive in the cytoplasm.[2] A separate line of research reported that in a crystal-induced peritonitis model, KPV's antimigratory effect on immune cells was not blocked by melanocortin receptor antagonists, supporting the receptor-independent mechanism proposed for this fragment specifically.[1] Notably, KPV is transported into intestinal cells via the PepT1 peptide transporter, which researchers report allows it to remain active when administered orally — a pharmacokinetic property distinct from most peptides, which typically require injection to avoid gastrointestinal degradation.[2]

Research Domains

  • Receptor-independent signaling research — studies report KPV's anti-inflammatory activity persists independent of melanocortin receptor binding, distinguishing its mechanism from full-length alpha-MSH.[1]
  • Inflammatory bowel disease research — oral KPV reduced disease severity in DSS- and TNBS-induced colitis mouse models, with research attributing gastrointestinal activity to PepT1-mediated cellular uptake.[2]
  • Murine IBD model research — a separate study in murine IBD models reported KPV treatment was associated with earlier recovery, reduced weight loss, and reduced inflammatory infiltrate in colonic tissue.[3]
  • Immunomodulatory review literature — review literature positions KPV and related alpha-MSH-derived peptides as a distinct class of anti-inflammatory and immunomodulating research compounds.[4]

Comparative Notes

KPV is mechanistically distinct from the other repair-focused peptides in this catalog. Where BPC-157 is studied for VEGFR2/angiogenesis-linked tissue-repair pathways, KPV's research basis centers on NF-κB inhibition and receptor-independent anti-inflammatory signaling — a separate mechanism relevant to inflammatory rather than structural repair research questions.

KPV product page →

Certificate of Analysis: What to Look For

A Certificate of Analysis for a KPV research vial should report, at minimum: confirmed amino acid sequence (typically via mass spectrometry) and net peptide content. Vials should be stored lyophilized at -20°C, protected from light, consistent with handling guidance for the other lyophilized peptides in this catalog.

References

  1. Getting SJ, Schiöth HB, Perretti M (2003). Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. Journal of Pharmacology and Experimental Therapeutics. PMID: 12750433
  2. Dalmasso G, Charrier-Hisamuddin L, Nguyen HTT, Yan Y, Sitaraman S, Merlin D (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. PMID: 18061177
  3. Kannengiesser K, Maaser C, Heidemann J, Luegering A, Ross M, Brzoska T, Bohm M, Luger TA, Domschke W, Kucharzik T (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases. PMID: 18092346
  4. Luger TA, Brzoska T (2007). alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs. Annals of the Rheumatic Diseases. PMID: 17934097

FAQ

KPV is a naturally occurring tripeptide corresponding to residues 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH).[1]

No. Research reports KPV does not bind melanocortin receptors or increase intracellular cAMP, meaning its studied anti-inflammatory effects are receptor-independent.[1]

Research centers on inhibition of NF-κB activation by preventing IκBα degradation in intestinal epithelial and immune cell models.[2]

Inflammatory bowel disease research is the most extensively studied domain, with multiple mouse colitis models reporting reduced disease severity following KPV treatment.[2][3]

A COA for a KPV research vial should report confirmed amino acid sequence and net peptide content, consistent with the documentation standard used across this catalog.

No. KPV is supplied strictly under a Research Use Only framework for laboratory and preclinical investigation, and none of the studies referenced here involve clinical administration guidance.

Related Guides